Abiopharma

🔍 RA CAPITAL MANAGEMENT, L.P. (Executive)

Company: Inhibikase Therapeutics, Inc. (IKT)

Report Date: 2026-07-29

Detailed Transactions and Holdings:

• Sold 18,030,000 shares of Common Stock (Direct)
  Date: 2026-07-29 | Code: J | equity_swap_involved: 0 | shares_owned_after: 6,970,000.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2
• Acquired 18,030,000 shares of Pre-Funded Warrant (Right to Buy) at $0.001 per share (Derivative)
  Date: 2026-07-29 | Code: J | equity_swap_involved: 0 | shares_owned_after: 18,030,000.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4, F4, F2

Footnotes:

• F1: On July 29, 2026, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 18,030,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 18,030,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the "Pre-Funded Warrant").
• F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
• F3: Held directly by the Fund.
• F4: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.